● Semaglutide · type 2 diabetes
Ozempic review with structured medical follow-up
- English-speaking diabetes review
- Telephone or secure video consultation
- Established treatment and monitoring
- Electronic prescription when appropriate
Ozempic is authorised for adults with insufficiently controlled type 2 diabetes. It is not presented here as a routine substitute for medicines authorised specifically for weight management.
Prescription medicineClinical assessment requiredType 2 diabetesAuthorised indicationFollow-upMonitoring and toleranceNo automatic prescriptionIndividual decision
Ozempic explainedWhat it containsSemaglutide in a pre-filled injection pen. Authorised useAdults with insufficiently controlled type 2 diabetes, alongside diet and exercise. How it is takenA once-weekly injection, with dosage changed only under medical supervision.
What Ozempic is, what it contains and when it is used
Ozempic is a prescription medicine containing semaglutide. Semaglutide is a GLP-1 receptor agonist that helps the pancreas release insulin when blood glucose is high, reduces glucagon and slows gastric emptying.
Ozempic and Wegovy contain the same active ingredient, but they are authorised for different purposes and follow different dose schedules. They should not be treated as interchangeable pens.
Same active ingredient, different pathways
Ozempic versus Wegovy: the differences that matter
Both medicines contain semaglutide, but their authorised indications, evidence base and dose schedules are different.
Slide right to see the full comparison
| Clinical point | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Authorised purpose | Type 2 diabetes that is not sufficiently controlled, as an adjunct to diet and exercise. | Weight management, together with a reduced-calorie diet and increased physical activity, for eligible adults and adolescents. |
| Starting schedule | Usually 0.25 mg once weekly for four weeks, then 0.5 mg once weekly. | Usually 0.25 mg once weekly, followed by staged increases at four-week intervals. |
| Higher doses | When needed for glycaemic control, the authorised schedule can progress to 1 mg and then 2 mg after the required time at each preceding dose. | The weight-management schedule progresses through 0.5 mg, 1 mg and 1.7 mg towards a 2.4 mg maintenance dose, subject to tolerance and clinical review. |
| Why the doses diverge | The dose ladders were studied and authorised for different treatment goals. A dose from one brand must not be converted or copied across without a clinician reviewing the indication, current treatment and safety. | |
| Important limitation | Ozempic is not presented here as a routine weight-loss prescription. | Wegovy has specific BMI and health criteria for weight-management eligibility. |
Do not change brands, combine semaglutide products or alter the dose yourself. The prescribing doctor must assess the diagnosis, current dose, response, side effects and the safest timing of any change.
Correct route
When Ozempic review may be relevant
This pathway is intended for people with type 2 diabetes who need clinical review of established Ozempic treatment or a diabetes-care discussion. People seeking licensed medical weight-management treatment should review the Wegovy and Mounjaro pathways.
- Bring evidence of diagnosis and current treatment
- Prepare recent blood results when available
- List other medicines and side effects
- Prescription only when clinically appropriate
Common questions
Questions about Ozempic review
Is Ozempic authorised for weight loss?
Ozempic is authorised in the EU for type 2 diabetes. Wegovy is the semaglutide brand authorised for weight management.
Can established treatment be reviewed online?
Often, when sufficient clinical evidence and monitoring information are available.
Is a prescription guaranteed?
No. The doctor decides after reviewing diagnosis, history, treatment and safety.
Do I need blood tests?
The doctor may request recent monitoring or recommend local tests depending on your diabetes care.
Can I change from Ozempic to Wegovy?
The doctor must review the indication, current dose, treatment response and timing before any change.
What information should I prepare?
Prepare evidence of type 2 diabetes, the current prescription, recent monitoring and a complete medicine list.
How often is follow-up needed?
Follow-up depends on diabetes control, dosage, tolerance and the monitoring requested by the doctor.
What if Ozempic is unavailable?
Do not substitute another product or alter the dose without a clinical review.
Medically reviewed
Dr Ben Harry Clegg
General practitioner · Málaga registration 292911940 · Nerja Medical Center NICA 55712
Meet the telehealth medical teamOfficial sources checked 30 August 2026: European Medicines Agency — Ozempic product information and European Medicines Agency — Wegovy product information.